


LABQUALITY

Quality Assessment Services - EQA & IQA
Microbiology & Immunology Portfolio



EQA Services

Labquality is a recognized provider of professional external quality assessment (EQA) services and quality controls for internal quality assurance (IQA). Altogether more than 150 schemes are available for various fields of laboratory medicine and about 75 for microbiology. With its comprehensive and growing portfolio, Labquality provides a one-stop shop for laboratory quality assurance.

EQA provides participants a means of assessing their analytical performance in comparison to other laboratories using the same methods and instruments. The service includes provision of identical specimens to all participants, statistical analysis of the results and feedback to the participants on their performance.

Portfolio Highlights

75 Schemes for Microbiology & Immunology

- Antigen detection
- Antibody detection
- Culture - Identification & Susceptibility
- Nucleic acid amplification testing
- POCT
- Preanalytics & Postanalytics

New Schemes

- Molecular testing: HBV DNA, HCV RNA and HIV RNA
- Multidrug resistant bacteria - MRSE, VRE & Gramnegative rods
- Multiplex detection of *C. trachomatis* and *N. gonorrhoeae*



Microbiological and Immunological Schemes

		Antibody detection	Antigen detection	Culture / Identification	Culture / Susceptibility	NAT	POCT	Staining / Microscopy	Pre-analytics	Post-analytics
BACTERIOLOGY										
5050	Bacteriological staining, direct							x		
5100	Blood culture			x	x					
5101	Blood culture, screening			(x)						
5150	Cerebrospinal fluid, culture, screening			(x)						
5612	<i>C. trachomatis</i> and <i>N. gonorrhoeae</i> , nucleic acid detection					x				
5610	<i>C. trachomatis</i> , nucleic acid detection					x				
5200	<i>Clostridium difficile</i> , culture and toxin detection		x	x		x				
5190	Faecal culture			x						
5080	General bacteriology 1 (aerobes and anaerobes)			x	x					
5081	General bacteriology 2 (aerobes)			x	x					
5040	Gram stain, colonies							x	x	
5041	Gram stain, blood culture, methods without carbon							x	x	
5042	Gram stain, blood culture, methods with carbon							x	x	
5596	<i>Helicobacter pylori</i> , antigen detection in faeces		x				x			
5597	<i>Legionella</i> , antigen detection in urine		x				x			
5220	Mycobacterial culture and smear			x				x		
5240	Mycobacterial smear							x		
5120	<i>Neisseria gonorrhoeae</i> (Gc), culture and susceptibility testing			x	x					
5180	<i>Salmonella</i> , culture			x						
5595	<i>Streptococcus</i> (group A), antigen detection		x				x			
5598	<i>Streptococcus pneumoniae</i> , antigen detection in urine		x				x			
5071	Surveillance culture for multidrug-resistant bacteria, MRSA			x	x	x				
5072	Surveillance culture for multidrug-resistant bacteria, VRE			x	x	x				
5073	Surveillance culture for multidrug-resistant bacteria, gramnegative rods			x	x	x				
5140	Throat streptococcal culture, screening and identification			x						
5060	Urine culture, quantitative, screening			(x)						
5065	Urine culture, quantitative, screening, identification and susceptibility			x	x					
BACTERIAL SEROLOGY										
5840	Antistreptolysin titre									P/N
5950	<i>Bordetella pertussis</i> , antibodies	x								INT
5960	<i>Borrelia burgdorferi</i> , antibodies	x								INT
5620	<i>Chlamydia pneumoniae</i> , antibodies	x								INT
5970	Enteropathogens, antibodies	x								
5860	<i>Helicobacter pylori</i> , antibodies	x								INT
5980	<i>Mycoplasma pneumoniae</i> , antibodies	x								INT
5880	Syphilis serology	x								INT
IMMUNOLOGY										
5935	ANCA and GbmAb	x								
5900	Antinuclear antibodies	x								
5940	Coeliac disease, antibodies	x								
5930	Autoimmune liver disease and gastric parietal cell antibodies	x								
5937	Phospholipid antibodies	x								
5820	Rheumatoid factor and citrullin peptide antibodies	x								
5920	Thyroid gland antibodies	x								
5913	Thyroid stimulating hormone receptor, antibodies	x								

		Antibody detection	Antigen detection	Culture / Identification	Culture / Susceptibility	NAT	POCT	Staining / Microscopy	Pre-analytics	Post-analytics
MYCOLOGY										
5260	Fungal culture			x	x			(x)	BG	
PARASITOLOGY										
5460	Parasites in blood, Giemsa stain							x		
5461	Parasites in blood, May-Grünwald-Giemsa stain							x		
5470	Parasites in blood, Giemsa stain, virtual microscopy							VM		
5471	Parasites in blood, May-Grünwald-Giemsa stain, virtual microscopy							VM		
5440	Parasites in faeces							x	BG	
5450	Parasites in faeces, virtual microscopy							VM	BG	
5430	Malaria, antigen detection, POCT		x				x			
5420	<i>Toxoplasma</i> , antibodies	x							BG	INT
VIROLOGY										
5650	Cytomegalovirus, antibodies	x								INT
5641	EBV, specific antibodies	x								INT
5640	EBV mononucleosis, heterophile antibodies, POCT						x			
5092	Hepatitis A, antibodies	x	x							INT
5094	Hepatitis B and C, specimen volume 0.6ml	x	x							INT
5095	Hepatitis B and C, specimen volume 1.2ml	x	x							INT
5096	Hepatitis B and C, specimen volume 2.0ml	x	x							INT
5093	Hepatitis B, s-antigen antibodies, quantitative	x								INT
5679	Hepatitis B virus, DNA					x				
5678	Hepatitis C virus, RNA					x				
5555	Herpes simplex 1 and 2, antibodies	x								
5680	HIV, RNA					x				
5091	HIV, antibodies	x								INT
5090	HIV, antibodies, POCT	x					x			
5089	Human T-cell lymphotropic virus, antibodies	x								INT
5671	Influenza virus A + B, detection		x			x	x			
5668	Measles virus, antibodies	x								INT
5669	Mumps virus, antibodies	x								INT
5660	Parvovirus (B19), antibodies	x								INT
5560	Puumala virus, antibodies	x					x			INT
5098	Rotavirus and adenovirus, antigen detection		x							
5672	RS-virus, detection		x			x	x			
5667	Rubella virus, antibodies	x								INT
5099	Tick-borne encephalitis virus, antibodies	x								INT
5665	Varicella-zoster virus, antibodies	x								INT

BG = Case histories or background information provided

INT = Clinical interpretation as part of the examinations

P/N = Interpretation for positivity/negativity

VM = Virtual microscopy

Schemes highlighted in blue = New schemes launching in 2014

Scheme Details

Bacterial Serology

5840 Antistreptolysin

Rounds: 4 - Feb, May, Aug, Nov
Specimens: 2 liquid human sera or plasma, 0.4 mL ea
Examinations: Qualitative and quantitative ASO
Reports: Expert comments, laboratory specific summary, scoring report

5950 Bordetella pertussis, antibodies

Rounds: 4 - Jan, Apr, Aug, Nov
Specimens: 2 liquid human sera, 0.4 mL ea
Examinations: *B. pertussis* IgA, IgG & IgM antibodies, Pertussis toxin IgA, IgG & IgM and clinical interpretation
Reports: Expert comments, laboratory specific summary, scoring report

5960 Borrelia burgdorferi, antibodies, European origin

Rounds: 4 - Jan, Apr, Aug, Nov
Specimens: 2 liquid human sera or plasma, 0.5 mL ea
Examinations: *B. burgdorferi* IgG, IgM and total antibodies, clinical interpretation
Reports: Expert comments, laboratory specific summary, scoring report

5620 Chlamydia pneumoniae, antibodies

Rounds: 4 - Feb, May, Aug, Nov
Specimens: 3 liquid human sera or plasma, 0.3 mL ea
Examinations: *C. pneumoniae* IgA, IgG, IgM antibodies, clinical interpretation
Reports: Expert comments, laboratory specific summary, scoring report

5970 Enteropathogens, antibodies

Rounds: 4 - Feb, May, Sep, Dec
Specimens: 2 liquid human sera or plasma, 0.6 mL ea
Examinations: Salmonella and yersinia IgA, IgG, IgM and total antibodies, clinical interpretation
Reports: Expert comments, laboratory specific summary, scoring report

5860 Helicobacter pylori, antibodies

Rounds: 4 - Mar, Jun, Sep, Dec
Specimens: 2 liquid human sera or plasma, 0.4 mL ea
Examinations: *H. pylori* IgA, IgG and total antibodies, quantitative and qualitative tests, clinical interpretation
Reports: Expert comments, laboratory specific summary, scoring report

5980 Mycoplasma pneumoniae, antibodies

Rounds: 4 - Feb, May, Sep, Nov
Specimens: 2 liquid human sera, 0.3 mL ea
Examinations: *M. pneumoniae* IgG, IgM and total antibodies, clinical interpretation
Reports: Expert comments, laboratory specific summary, scoring report

5880 Syphilis serology

Rounds: 4 - Feb, Jun, Oct, Dec
Specimens: 2 liquid human sera or plasma, 0.6 mL ea
Examinations: Cardiolipin, *Treponema pallidum* antibodies and clinical interpretation
Reports: Expert comments, laboratory specific summary

Why Labquality EQAS?

- Schemes to all fields of laboratory medicine
- Independency
- High quality specimens
- Flexibility in participation

Bacteriology

5050 Bacteriological staining, direct

Rounds: 2 - Apr, Oct
Specimens: 3 digital pictures
Examinations: Interpretation of digital pictures taken from direct bacteriological staining of clinical samples
Reports: Expert comments, laboratory specific summary, scoring report
Notes: The results are entered via Labquality's website

5100 Blood culture

Rounds: 4 - Mar, May, Oct, Dec
Specimens: 2 lyophilized specimens with brief case histories also given. Fresh blood is needed in the specimen preparation. The specimens intended for susceptibility testing may include both international quality control strains and clinical strains such as VRE and MRSA.
Examinations: Culture, identification, antimicrobial susceptibility
Reports: Expert comments, laboratory specific summaries, scoring report

5101 Blood culture, screening

Rounds: 4 - Mar, May, Oct, Dec
Specimens: 2 lyophilized specimens with brief case histories also given. Fresh blood is needed in the specimen preparation.
Examinations: Culture, preliminary identification using Gram stain. The scheme is also suitable for stem cell banks screening only for possible growth.
Reports: Expert comments, laboratory specific summaries, scoring report

5150 Cerebrospinal fluid, culture, screening

Rounds: 4 - Mar, May, Sep, Dec
Specimens: 2 lyophilized specimens with brief case histories also given
Examinations: Culture, preliminary identification using Gram stain. The scheme is also suitable for laboratories performing identification.
Reports: Expert comments, laboratory specific summaries, scoring report

5612 Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid detection

Rounds: 4 - Apr, Jun, Sep, Dec
Specimens: 3 specimens (swab and/or liquid samples)
Examinations: Detection of *C. trachomatis* and *N. gonorrhoeae* nucleic acid
Reports: Expert comments, laboratory specific summaries, scoring report
Notes: Scheme is designed for multiplex assays. Laboratories performing only *C. trachomatis* testing should order product 5610.

5610 Chlamydia trachomatis, nucleic acid detection

Rounds: 4 - Apr, Jun, Sep, Dec
Specimens: 3 specimens (swab and/or liquid samples)
Examinations: Detection of *C. trachomatis* nucleic acid
Reports: Expert comments, laboratory specific summaries, scoring report

5200 Clostridium difficile, culture and toxin detection

Rounds: 4 - Mar, May, Aug, Nov
Specimens: 2 lyophilized mixtures of bacteria
Examinations: Culture and/or toxin detection (enterotoxin A, cytotoxin B)
Reports: Expert comments, laboratory specific summaries, scoring report

5190 Faecal culture

Rounds: 4 - Apr, Jun, Oct, Dec
Specimens: 2 lyophilized mixtures of bacteria with brief case histories also given
Examinations: Culture and identification Pathogens included are EHEC, Campylobacter, Salmonella, Shigella and Yersinia
Reports: Expert comments, laboratory specific summaries, scoring report

5080 General Bacteriology 1 (aerobes and anaerobes)

Rounds: 4 - Mar, May, Sep, Dec
Specimens: 4 lyophilized mixtures of microbes; both pathogens and normal flora. The specimens intended for susceptibility testing may include both international quality control strains and clinical strains such as VRE and MRSA. Brief case histories are also given.
Examinations: Isolation of pathogens and antimicrobial susceptibility testing
Reports: Expert comments, laboratory specific summaries, scoring report
Note: 5080 General Bacteriology 1 also includes 5081, General Bacteriology 2

5081 General Bacteriology 2 (aerobes)

Rounds: 4 – Mar, May, Sep, Dec
Specimens: 2 lyophilized mixtures of microbes; both pathogens and normal flora. The specimens intended for susceptibility testing may include both international quality control strains and clinical strains such as VRE and MRSA. Brief case histories are also given.
Examinations: Isolation of pathogens and antimicrobial susceptibility testing
Reports: Expert comments, laboratory specific summaries, scoring report
Note: 5080 General Bacteriology 1 also includes 5081 General Bacteriology 2

5040 Gram stain, colonies

Rounds: 4 – Jan, Apr, Jul, Oct
Specimens: 3 air-dried, unfixed microbe suspensions on a slide
Examinations: Staining and microscopy
Reports: Expert comments, laboratory specific summaries, scoring report

5041 Gram stain, blood culture, methods without carbon

Rounds: 4 – Jan, Apr, Jul, Oct
Specimens: 2-3 air-dried microbe suspensions on slides
Examinations: Staining and microscopy
Reports: Expert comments, laboratory specific summaries, scoring report

5042 Gram stain, blood culture, methods with carbon

Rounds: 4 – Jan, Apr, Jul, Oct
Specimens: 2-3 air-dried microbe suspensions on slides
Examinations: Staining and microscopy
Reports: Expert comments, laboratory specific summaries, scoring report

5596 *Helicobacter pylori*, antigen detection in faeces

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: 3 lyophilized faecal specimens
Examinations: Antigen detection
Reports: Expert comments, laboratory specific summaries, scoring report
Note: For both clinical laboratories and POCT units

5597 Legionella, antigen detection in urine

Rounds: 4 – Mar, May, Sep, Dec
Specimens: 3 simulated urine specimens
Examinations: Legionella antigen detection
Reports: Expert comments, laboratory specific summaries, scoring report

5220 Mycobacterial culture and smear

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: 2 lyophilized specimens & 2 fixed smears on slides
Examinations: Detection of *Mycobacterium tuberculosis* and atypical mycobacteria: culture, acid-fast staining and microscopy
Reports: Expert comments, laboratory specific summaries, scoring report

5240 Mycobacterial smear

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: 2 fixed smears on slides
Examinations: Acid-fast staining and microscopy
Reports: Expert comments, laboratory specific summaries, scoring report

5120 *Neisseria gonorrhoeae* (Gc), culture and susceptibility testing

Rounds: 4 – Mar, May, Aug, Nov
Specimens: 2 lyophilized mixtures of microbes in loops
Examinations: Culture and identification. Also suitable for laboratories performing preliminary screening. Susceptibility testing.
Reports: Expert comments, laboratory specific summaries, scoring report

5180 Salmonella culture

Rounds: 4 – Apr, Jun, Oct, Dec
Specimens: 2 lyophilized mixtures of bacteria with brief case histories also given
Examinations: Culture and identification
Reports: Expert comments, laboratory specific summaries, scoring report
Note: 5190, Faecal culture also includes Salmonella culture

5595 Streptococcus (group A), antigen detection

Rounds: 4 – Mar, May, Sep, Dec
Specimens: 3 simulated pharyngeal specimens
Examinations: Antigen detection
Reports: Expert comments, laboratory specific summaries, scoring report
Note: For both clinical laboratories and POCT units

5598 *Streptococcus pneumoniae*, antigen detection in urine

Rounds: 4 – Mar, May, Sep, Dec
Specimens: 3 simulated urine specimens
Examinations: *S. pneumoniae* antigen detection
Reports: Expert comments, laboratory specific summaries, scoring report

5071 Surveillance culture for multidrug resistant bacteria, MRSA

Rounds: 4 – Mar, Jun, Sep, Nov
Specimens: 1 lyophilized mixture of microbes; including pathogens and/or normal flora
Examinations: The scheme is intended for laboratories performing screening of MRSA (methicillin resistant *Staphylococcus aureus*). The scheme is suitable both for culture and direct detection from specimen using molecular methods.
Reports: Expert comments, laboratory specific summaries, scoring report
Notes: The scheme is delivered simultaneously with products 5072 and 5073

5072 Surveillance culture for multidrug resistant bacteria, VRE

Rounds: 4 – Mar, Jun, Sep, Nov
Specimens: 1 lyophilized mixture of microbes; including pathogens and/or normal flora
Examinations: The scheme is intended for laboratories performing screening of VRE (vancomycin-resistant enterococci). The scheme is suitable both for culture and direct detection from specimen using molecular methods.
Reports: Expert comments, laboratory specific summaries, scoring report
Notes: The scheme is delivered simultaneously with products 5071 and 5073

5073 Surveillance culture for multidrug resistant bacteria, gramnegative rods

Rounds: 4 – Mar, Jun, Sep, Nov
Specimens: 1 lyophilized mixture of microbes; including pathogens and/or normal flora
Examinations: The scheme is intended for laboratories performing screening of multidrug resistant gramnegative rods (e.g. CPE, ESBL, MDR Acinetobacter and *P. aeruginosa*). The scheme is suitable both for culture and direct detection from specimen using molecular methods.
Reports: Expert comments, laboratory specific summaries, scoring report
Notes: The scheme is delivered simultaneously with products 5071 and 5072

5140 Throat streptococcal culture, screening and identification

Rounds: 4 – Mar, May, Aug, Nov
Specimens: 3 lyophilized mixtures of bacteria
Examinations: Culture and identification
Reports: Expert comments, laboratory specific summaries, scoring report

5060 Urine culture, quantitative, screening

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: 2 lyophilized specimens and dilutor with brief case histories also given
Examinations: Screening
Reports: Expert comments, laboratory specific summaries, scoring report

5065 Urine culture, quantitative, screening, identification and susceptibility

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: 2 lyophilized specimens and dilutor with brief case histories also given. The specimens intended for susceptibility testing may include both international quality control strains and clinical strains such as VRE and MRSA.
Examinations: Culture, identification and antimicrobial susceptibility testing
Reports: Expert comments, laboratory specific summaries, scoring report

Immunology

5935 ANCA and GbmAb

Rounds: 2 – Feb, Aug
Specimens: 2 liquid human sera or plasma, ~0.5 mL ea
Examinations: Anti-neutrophilic cytoplasmic antibodies, Myeloperoxidase antibodies, Proteinase-3 antibodies and Glomerular basement membrane antibodies.
Reports: Expert comments, laboratory specific summaries

5900 Antinuclear antibodies

Rounds: 2 – May, Oct
Specimens: 3 liquid human sera or plasma, ~0.6 mL ea
Examinations: ANA, ENAAb, RNPAb, SmAb, SSAAb, SSBAb, Scl70Ab, CentAb, Jo1Ab, DNAnAb (dsDNA), HistAb.
Reports: Expert comments, laboratory specific summaries
Note: Extractable antinuclear antigens and double-stranded deoxyribonucleic acid are included

5940 Coeliac disease, antibodies

Rounds: 3 – Feb, Jun, Oct
Specimens: 2 liquid human sera or plasma, ~0.7 mL ea
Examinations: Endomysium antibodies, tissue transglutaminase antibodies, deamidated gliadin peptide antibodies
Reports: Expert comments, laboratory specific summaries

5930 Autoimmune liver disease and gastric parietal cell antibodies

Rounds: 2 – May, Nov
Specimens: 2 liquid human sera or plasma, ~0.4 mL ea
Examinations: Liver kidney microsomal antibodies, Smooth muscle antibodies, Mitochondrial antibodies, Gastric parietal cell antibodies
Reports: Expert comments, laboratory specific summaries

5937 Phospholipid antibodies

Rounds: 1 – May
Specimens: 2 liquid human sera or plasma, ~0.5 mL ea
Examinations: Phospholipid antibodies, Cardiolipin antibodies (IgG and IgM), beta-2-glycoprotein antibodies (IgG)
Reports: Expert comments, laboratory specific summaries

5820 Rheumatoid factor and citrullin peptide antibodies

Rounds: 4 – Jan, Apr, Jul, Oct
Specimens: 2 liquid human sera or plasma, ~0.7 mL ea
Examinations: Qualitative and quantitative RF, cyclic citrullinated peptide antibodies
Reports: Histograms and expert comments. Interpretation summary and scoring report (if interpretation is reported).
Note: Results are entered via Labquality's internet pages

5920 Thyroid gland antibodies

Rounds: 3 – Mar, Jun, Oct
Specimens: 2 liquid human sera or plasma, ~0.4 mL ea
Examinations: Thyroglobulin antibodies and thyroid peroxidase antibodies
Reports: Expert comments, laboratory specific histograms and tables, numeric summary



5913 Thyroid stimulating hormone receptor antibodies

Rounds: 2 – Mar, Sep
Specimens: 2 liquid human sera, 0.4 mL each
Examinations: Thyroid stimulating hormone receptor antibodies
Reports: Expert comments, laboratory specific histograms and tables, numeric summary

Mycology

5260 Fungal culture

Rounds: 4 – Mar, May, Sep, Dec
Specimens: 3 lyophilized specimens with brief case histories also given. The specimens include moulds, dermatophytes and yeasts
Examinations: Culture and identification. Antimicrobial susceptibility of yeast strains
Reports: Expert comments, laboratory specific summaries. Table of susceptibility, results by methods, scoring report.



Virtual Microscopy

Virtual microscopy involves imaging representative microscope specimens which participants view on their computer screen. Viewing of several fields of vision and levels of focus are enabled to simulate analysis with an optical microscope. Thanks to technical advantages, viewing is now enabled even with a cellular phone.

Virtual microscopy provides a powerful tool for disciplines traditionally limited by the homogeneity and size of the specimen. At present, Labquality offers four virtual microscopy based EQA schemes, among them Giemsa and MGG stains for Parasites in blood.

Original view on samples used in the Parasites in blood virtual microscopy scheme. Top: Three amoeboid *P. vivax* infected red cells with red chromatin and blue cytoplasm. Bottom: Close-up view into infected cells. ----->

Parasitology

5460 Parasites in blood, Giemsa stain

Rounds: 4 – Feb, May, Aug, Nov
Specimens: 2 Giemsa stained smears. Brief case histories are also given. Authentic specimens.
Examinations: Screening and identification of malaria plasmodia and other blood parasites
Reports: Expert comments, laboratory specific summaries, scoring report

5461 Parasites in blood, May-Grünwald-Giemsa stain

Rounds: 4 – Feb, May, Aug, Nov
Specimens: 2 MGG stained smears. Brief case histories are also given. Authentic specimens.
Examinations: Screening and identification of malaria plasmodia and other blood parasites
Reports: Expert comments, laboratory specific summaries, scoring report

5470 Parasites in blood, Giemsa stain, virtual microscopy

Rounds: 2 – Apr, Oct
Specimens: Virtual whole slide images of Giemsa stained smears prepared by using a scanner microscope.
Examinations: Screening and identification of malaria plasmodia and other blood parasites.
Reports: Expert comments, laboratory specific summaries
Note: Virtual microscopy scheme. Please check the system requirements on Labquality's Internet pages.

5471 Parasites in blood, May-Grünwald-Giemsa stain, virtual microscopy

Rounds: 2 – Apr, Oct
Specimens: Virtual whole slide images of MGG stained smears prepared by using a scanner microscope.
Examinations: Screening and identification of malaria plasmodia and other blood parasites.
Reports: Expert comments, laboratory specific summaries
Note: Virtual microscopy scheme. Please check the system requirements on Labquality's Internet pages.

5440 Parasites in faeces

Rounds: 4 – Feb, May, Aug, Nov
Specimens: 3 stool specimens in formalin with brief case histories also given
Examinations: Screening and identification of intestinal parasites (ova and parasites)
Reports: Expert comments, laboratory specific summaries, scoring report

5450 Parasites in faeces, virtual microscopy

Rounds: 2 – Apr, Oct
Specimens: Virtual whole slide images of stool specimens in formalin prepared by using a scanner microscope
Examinations: Screening and identification of intestinal parasites (ova and parasites)
Reports: Expert comments, laboratory specific summaries
Note: Virtual microscopy scheme. Please check the system requirements on Labquality's Internet pages.

5430 Malaria, antigen detection

Rounds: 4 – Jan, Apr, Aug, Nov
Specimens: 3 whole blood specimens
Examinations: Antigen detection
Reports: Expert comments, laboratory specific summaries, scoring report
Note: Both for clinical laboratories and POCT units

5420 Toxoplasma, antibodies

Rounds: 4 – Feb, May, Aug, Nov
Specimens: 3 liquid human plasma, 0.7 mL each with brief case histories also given. Authentic commutable specimens: Each specimen batch originates from a single human donor.
Examinations: IgA, IgG and IgM antibodies, avidity and clinical interpretation
Reports: Expert comments, laboratory specific summaries, scoring report
Note: Results are entered via Labquality's website

Virology

5650 Cytomegalovirus, antibodies

Rounds: 4 – Feb, May, Sep, Dec
Specimens: 3 liquid human plasma, > 0.7 mL ea. Authentic commutable specimens: Each specimen batch originates from a single human donor.
Examinations: Cytomegalovirus IgG, IgM and total antibodies, IgG avidity and clinical interpretation
Reports: Expert comments, laboratory specific summaries, scoring report
Note: Results are entered via Labquality's website

5640 EBV mononucleosis, heterophile antibodies

Rounds: 4 – Feb, May, Sep, Dec
Specimens: 3 liquid human plasma, 0.5 mL ea. Authentic commutable specimens: Each specimen batch originates from a single human donor.
Examinations: MonAb, heterophile antibodies
Reports: Expert comments, laboratory specific summaries, scoring report
Note: Both for clinical laboratories and POCT units

5641 EBV mononucleosis, specific antibodies

Rounds: 4 – Feb, May, Sep, Dec
Specimens: 3 liquid human plasma, 1.2 mL ea. Authentic commutable specimens: Each specimen batch originates from a single human donor.
Examinations: EBNAAb, EBVAb, EBVAbG, EBVAbM, EBVAvi. Specific antibodies; clinical interpretation.
Reports: Expert comments, laboratory specific summaries, scoring report

5092 Hepatitis A, antibodies

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: 3 liquid human plasma, > 0.7 mL ea. Authentic commutable specimens: Each specimen batch originates from a single human donor.
Examinations: HAVAb, HAVAbM, HAVAbG and clinical interpretation
Reports: Expert comments, laboratory specific summaries, scoring report
Note: Results are entered via Labquality's website

5093 Hepatitis B, s-antigen antibodies, quantitative

Rounds: 4 – Jan, Apr, Jul, Oct
Specimens: 2 liquid human plasma or sera 0.5 mL ea. Authentic commutable specimens: Each specimen batch originates from a single human donor.
Examinations: HBsAb (anti-HBs), quantitative
Reports: Expert comments, laboratory specific histograms, youden plots and summaries, scoring report

5094-5096 Hepatitis B and C, serology, specimen volume 0.6 mL / 1.2 mL / 2.0 mL

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: 3 liquid human plasmas, 0.6 / 1.2 or 2.0mL. Authentic commutable specimens: Each specimen batch originates from a single human donor.
Examinations: HBcAb, HBcAbM, HBeAb, HBeAg, HBsAb (qual), HBsAg, HCVAb, HCVAbCt and clinical interpretation
Reports: Expert comments, laboratory specific summaries, scoring report

Volume specific product codes
5094 for 0.6 mL human plasma specimens
5095 for 1.2 mL human plasma specimens
5096 for 2.0 mL human plasma specimens

5679 Hepatitis B virus, DNA

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: 3 plasma specimens, 1.2 mL/ea
Examinations: HBV DNA, quantitative and/or qualitative nucleic acid detection
Reports: Expert comments, laboratory specific summaries, scoring report
Note: Delivered together with 5678 & 5680

5678 Hepatitis C virus, RNA

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: Plasma, 3 specimens in each round, 1.2 mL/ea
Examinations: HCV RNA, quantitative and/or qualitative nucleic acid detection
Reports: Expert comments, laboratory specific summaries, scoring report
Note: Delivered simultaneously with 5679 & 5680

5555 Herpes simplex 1 and 2, antibodies

Rounds: 4 – Feb, May, Aug, Nov
Specimens: 3 liquid human plasma, > 0.5 mL ea. Authentic commutable specimens: Each specimen batch originates from a single human donor.
Examinations: HSVAb, HSVAbG (qualitative /quantitative), HSVAbM, HSV1AbG, HSV2AbG
Reports: Expert comments, laboratory specific summaries, scoring report

5091 HIV, antibodies

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: 4 liquid human plasma, > 0.7 mL each
Examinations: HIVAgAb (combo), HIVAb, HIVAbCt; primary and confirmatory tests, clinical interpretation. Positive specimens may include HIV-1 or HIV-2.
Reports: Expert comments, laboratory specific summaries, scoring report
Note: Results are entered via Labquality's internet pages

5090 HIV, antibodies, POCT

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: 3-4 liquid human plasma, > 0.5 mL ea
Examinations: HIVAb and HIVAgAb primary tests (POCT)
Reports: Expert comments, laboratory specific summaries, scoring report
Note: Results are entered via Labquality's internet pages. Scheme 5091 HI virus antibodies is for clinical laboratories

5680 HIV, RNA

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: 3 plasma specimens, 1.2 mL/vial
Examinations: HIV RNA, quantitative and/or qualitative nucleic acid detection
Reports: Expert comments, laboratory specific summaries, scoring report
Note: Delivered together with 5678 & 5679

5089 Human T-cell lymphotropic virus, antibodies

Rounds: 4 – Feb, May, Aug, Nov
Specimens: 3 liquid human plasma, > 0.5 mL ea. Authentic commutable specimens: Each specimen batch originates from a single human donor.
Examinations: HTLVAb; primary and confirmatory tests. Positive specimens may include HTLV-1 or HTLV-2
Reports: Expert comments, laboratory specific summaries, scoring report
Note: Results are entered via Labquality's internet pages

5671 Influenza virus A+B, detection

Rounds: 2 – Jan, Nov
Specimens: 3 artificial specimens, > 0.5 mL ea
Examinations: InfAAg, InfABA, InfBAg, InfA NAT, InfB NAT
Reports: Expert comments, laboratory specific summaries, scoring report
Note: Both for clinical laboratories and POCT units

5668 Measles virus, antibodies

Rounds: 4 – Jan, Apr, Jul, Oct
Specimens: 3 liquid human plasma, > 0.5 mL ea
Examinations: Measles virus IgG and IgM antibodies and clinical interpretation
Reports: Expert comments, laboratory specific summaries, scoring report

5669 Mumps virus, antibodies

Rounds: 4 – Jan, Apr, Jul, Oct
Specimens: 3 liquid human plasma, > 0.5 mL ea
Examinations: MumpsAb, MumpsAbG, MumpsAbM and clinical interpretation
Reports: Expert comments, laboratory specific summaries, scoring report

5660 Parvovirus B19, antibodies

Rounds: 4 – Feb, May, Aug, Nov
Specimens: 3 liquid human serum or plasma, 0.4 mL ea
Examinations: Parvovirus IgG, IgM and total antibodies, IgG avidity and clinical interpretation
Reports: Expert comments, laboratory specific summaries, scoring report

5560 Puumala virus, antibodies (Nephropathia epidemica)

Rounds: 4 – Mar, Jun, Oct, Dec
Specimens: 3 liquid human plasma or sera, > 0.3 mL ea. Brief case histories are also provided
Examinations: Puumala virus IgG, IgM and total antibodies, POC tests and specific antibodies, IgG avidity and clinical interpretation
Reports: Expert comments, laboratory specific summaries, scoring report
Note: For both clinical laboratories and POCT units

5098 Rotavirus and adenovirus, antigen detection

Rounds: 4 – Mar, Jun, Sep, Dec
Specimens: 3 faecal suspensions
Examinations: Direct rotavirus and adenovirus antigen detection
Reports: Expert comments, laboratory specific summaries, scoring report

5672 RS-virus, detection

Rounds: 2 – Jan, Nov
Specimens: 3 artificial specimens, 0.5 mL ea
Examinations: RSV NAT, RSVAg
Reports: Expert comments, laboratory specific summaries, scoring report
Note: For both clinical laboratories and POCT units

5667 Rubella virus, antibodies

Rounds: 4 – Jan, Apr, Jul, Oct
Specimens: 3 liquid human plasma or sera, ≥ 0.5 mL ea
Examinations: Rubella virus IgG and IgM antibodies, IgG avidity and clinical interpretation
Reports: Expert comments, laboratory specific summaries, scoring report

5099 Tick-borne encephalitis virus, antibodies

Rounds: 4 – Feb, May, Aug, Nov
Specimens: 3 human serum or plasmas, 0.5 mL ea. Authentic commutable specimens: Each specimen batch originates from a single human donor.
Examinations: TBEAb, TBEAbG, TBEAbM
Reports: Expert comments, laboratory specific summaries, scoring report

5665 Varicella-zoster virus, antibodies

Rounds: 4 – Feb, May, Aug, Nov
Specimens: 3 liquid human plasma or sera, ≥ 0.5 mL ea. Authentic commutable specimens: Each specimen batch originates from a single human donor.
Examinations: Varicella zoster IgG, IgM and total antibodies and clinical interpretation
Reports: Expert comments, laboratory specific summaries, scoring report

Scheme Reports

External quality assessment (EQA) provides participants a means of assessing their analytical performance in comparison to other laboratories using the same methods and instruments. Owing to the versatility of the schemes, the statistical analyses performed are scheme dependent and the reports may thus differ. In general, Labquality's reports include laboratory specific summaries, scoring reports and export comments. Examples of the reports are shown.

Example: Laboratory Specific Summary

sample comment: Specimen 346 SEP/13: Anti-HIV 2 positive. Specimen consisted of anti-HIV-2 positive donation diluted in a single anti-HIV negative donation.

raportin vaihtoehdot list only totals


Own result Expected result

	Negative / non reactive	Equivoaal	Positive / reaktive						
HIVAb, primary test	1	4	48						
HIV Ab/Ag Combo, primary test	-	1	201						
HIVAg (p24), primary test	2	-	3						
HIV Ab Confirmation test	-	16	-						
HIV-1 Ab Confirmation test	1	-	1						
HIV-2 Ab Confirmation test	-	-	5						
Clinical interpretation	-	-	4	7	19	3	175	-	18
Further handling	107	39							

The Laboratory specific summary includes comments on the specimen, expected results and a table of test results and interpretations. The results are presented for each analyte and method, expected results are green-shaded and the participant's own result is framed.

The scoring report includes two diagrams, one showing the scoring results of 0–90% (resolution 10%) and the other showing the results of 90–100% (resolution 1%). Laboratory's own placing is marked with a blue dot and shows in the 90-100% diagram for the below example.

Example: Scoring Report



specimen	analyte	own score	max score	own %	Difference (% points)	all laboratories
HIV 346 SEP/13	HIV Ab/Ag Combo, primary test	1	1	100 %	+1	99.5 %
	Clinical interpretation	2	2	100 %	+10	89.7 %
	Further handling	1	1	100 %	0	100.0 %
	Total of all analytes, all labs:	4	4	100 %	+7	93.3 %
Number of participants, not reported results:		23				
HIV 347 SEP/13	HIV Ab/Ag Combo, primary test	1	1	100 %	+1	99.5 %
	Clinical interpretation	2	2	100 %	+10	90.5 %
	Further handling	1	1	100 %	0	100.0 %
	Total of all analytes, all labs:	4	4	100 %	+6	94.1 %
Number of participants, not reported results:		24				
HIV 348 SEP/13	HIV Ab/Ag Combo, primary test	1	1	100 %	+1	99.0 %
	Clinical interpretation	2	2	100 %	+7	93.0 %
	Further handling	0	0	-	-	-
	Total of all analytes, all labs:	3	3	100 %	+4	95.7 %
Number of participants, not reported results:		24				
HIV 349 SEP/13	HIV Ab/Ag Combo, primary test	1	1	100 %	+1	99.5 %
	Clinical interpretation	2	2	100 %	+10	90.1 %
	Further handling	1	1	100 %	0	100.0 %
	Total of all analytes, all labs:	4	4	100 %	+6	94.0 %
Number of participants, not reported results:		23				

Internal Quality Assurance Controls

Labquality offers a range of third party quality controls and calibrators for *in vitro* diagnostic use. While being manufactured independently of all test systems, third party controls enable unbiased evaluation of the analytical performance.

Product Offering for Microbiology

StrAAg Control for Rapid Tests Detecting Streptococcus Group A Antigen (Labquality)

BI0000080 StrAAg Swab Positive Control

Thyroid Hormone Control (BIOREF)

BI00061491 Kit TH6 (TSH, T4, free T4, T3, free T3, Thyroglobulin), High/Mid/Low, 3 x 3 ml

ACCURUN 1 Series Controls for Multi-Analyte Bloodborne Virus Controls (SERACARE)

BBIA12408 ACCURUN 1 Series 2400 Multi Analyte Positive Control Abbott Prism

BBIA12603 ACCURUN 1 Series 2600 Multi Analyte Positive Control for Abbott AxSYM

BBIA15605 ACCURUN 1 Series 5600 Multi Analyte Positive Control for Roche Elecsys

ACCURUN 810 Multi-Analyte Serology Negative Control (SERACARE)

BBIA810xx ACCURUN 810 Multi-Marker Negative Control

ACCURUN ToRC(H) Control (SERACARE)

BBIACC025 ACCURUN 25 ToRCH IgG Positive Control

ACCURUN EBV Controls (SERACARE)

BBIACC030 ACCURUN 30 EBV IgG Positive Control

BBIACC031 ACCURUN 31 EBV IgM Positive Control

ACCURUN Hepatitis Controls (SERACARE)

BBIA515005 ACCURUN 51 Multi-Analyte Hepatitis Positive Control

BBIACC052 ACCURUN 52 Multi-Analyte Hepatitis Positive Control

BBIA1135005 ACCURUN 113 HBc IgM Positive Control

BBIA1205001 ACCURUN 120 Anti-HAV IgG Positive Control

BBIA305xx ACCURUN 305 Series 150 HCV RNA Positive Control

ACCURUN Rubella Controls (SERACARE)

BBIA1405001 ACCURUN 140 Anti-Rubella IgG Positive Control

BBIA1415004 ACCURUN 141 Anti-Rubella IgM Positive Control

ACCURUN CMV Controls (SERACARE)

BBIA1455004 ACCURUN 145 Anti-CMV IgG Positive Control

BBIA1465004 ACCURUN 146 Anti-CMV IgM Positive Control

ACCURUN HSV Control (SERACARE)

BBIA1505004 ACCURUN 150 Anti-HSV IgG Positive Control

ACCURUN HIV Controls (SERACARE)

BBIA1061003 ACCURUN 106 HIV-1 Ag Positive Control

BBIA315xx ACCURUN 315 HIV RNA Positive Control Series 150 – 200 copies/mL

BBIA3452124 ACCURUN 345 HIV-1 RNA, HCV RNA and HBV DNA Positive Control

ACCURUN HPV Controls (SERACARE)

BBIA3785030 ACCURUN 378 Series HPV DNA Positive Control

Note! Availability depends on region, contact Labquality or your distributor for details.

Labquality is a distributor of

